SCHEMBL7090800

SCHEMBL7090800

Nc1c(Nc2ccccn2)c(=O)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
MAPK10 P53779 1/20 0.50
GFER P55789 1/20 0.50
KMT2A Q03164 1/20 0.50
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MITF O75030 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
APAF1 O14727 1/20 0.44
TDP2 O95551 1/20 0.44
CDC25B P30305 1/20 0.44
CASP6 P55212 1/20 0.44
RCE1 Q9Y256 1/20 0.44
PLK1 P53350 1/20 0.44
PKM P14618 1/20 0.43
HTT P42858 1/20 0.42
NOD2 Q9HC29 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19957017 0.79 MEN1 (0.50) MEN1MAPK10GFERKMT2ANPC1
SCHEMBL14797051 0.76 ADRA1D (0.41) MEN1MAPK10GFERKMT2ANPC1
SCHEMBL221242 0.73 KMT2A (0.76) MEN1MAPK10GFERKMT2ANPC1
SCHEMBL29391624 0.73 KMT2A (0.76) MEN1MAPK10GFERKMT2ANPC1
SCHEMBL4025790 0.72 GAA (0.57) MEN1MAPK10GFERKMT2ANPC1
SCHEMBL7916081 0.71 CNR1 (0.47) PLK1
SCHEMBL7086950 0.71 SMN1; SMN2 (0.42) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL12682988 0.71 MEN1 (0.46) MEN1MAPK10GFERKMT2ANPC1
SCHEMBL6175584 0.71 KMT2A (0.73) MEN1MAPK10GFERKMT2ANPC1
SCHEMBL11133606 0.71 KMT2A (0.73) MEN1MAPK10GFERKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 EP disclosed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US disclosed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US disclosed
WO-2002062761-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165264-A1 Aminal diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 MEN1 773/4885MAPK10 2371/4885GFER 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.